Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Banco Bilbao Vizcaya Argentaria SATrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Banco Bilbao Vizcaya Argentaria SA trades at $28.72 (market cap $157.51B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 5.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 3.8% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYBBVA
Market Cap
$29.60B$157.51B
Sector
HealthFinancials
52-Week High
$491.22$28.50
52-Week Low
$205.48$17.96
Enterprise Value
$27.56B
Dividend Yield
3.8%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Banco Bilbao Vizcaya Argentaria SA

Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.

Read more on BBVA